Mark Eisner
CIK 1834161 · EVP and Chief Medical Officer · last filed 2026-06-26
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FGEN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
409 ILLINOIS STREET
SAN FRANCISCO, CA 94158
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| JBIO | Director | — | $14.81 | — | $0 | 1 | 2026-06-26 |
| ZURA | Director | — | $3.58 | — | $0 | 2 | 2026-06-22 |
| VIR | EVP and Chief Medical Officer | 155,913 | $10.45 | $1.63M | -$106.3K | 5 | 2026-02-26 |
| KYNTRA BIO, INC. (FGEN) Delisted | EVP, Chief Medical Officer | 6,397 | $9.75 | $62.4K | -$614.3K | 19 | 2023-09-08 |
Recent Filings · Page 3 of 4
35 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-04-06 | KYNTRA BIO, INC. (FGEN) Delisted | Sell (S) | −9,182 | -$172.5K | EDGAR |
| 2023-03-10 | KYNTRA BIO, INC. (FGEN) Delisted | Mixed | +2,680 | -$360.6K | EDGAR |
| 2023-03-06 | KYNTRA BIO, INC. (FGEN) Delisted | Sell (S) | −1,187 | -$26.0K | EDGAR |
| 2023-02-23 | KYNTRA BIO, INC. (FGEN) Delisted | Grant (A) | +32,500 | $0 | EDGAR |
| 2022-12-02 | KYNTRA BIO, INC. (FGEN) Delisted | Tax (F) | −1,084 | -$16.3K | EDGAR |
| 2022-10-04 | KYNTRA BIO, INC. (FGEN) Delisted | Tax (F) | −6,777 | -$88.2K | EDGAR |
| 2022-09-02 | KYNTRA BIO, INC. (FGEN) Delisted | Tax (F) | −756 | -$9.9K | EDGAR |
| 2022-06-03 | KYNTRA BIO, INC. (FGEN) Delisted | Tax (F) | −1,141 | -$11.0K | EDGAR |
| 2022-04-01 | KYNTRA BIO, INC. (FGEN) Delisted | Tax (F) | −6,442 | -$77.4K | EDGAR |
| 2022-03-03 | KYNTRA BIO, INC. (FGEN) Delisted | Tax (F) | −756 | -$10.3K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.